|Last Price$13.29||Day Change (%)0.30%|
|Open Price$13.29||Day Change ($)0.04|
|Day Range13.29–13.29||52-Week Range13.22–14.05|
As of Tue 12/06/2016 | USD
Tiziana Life Sciences Announces New Data with Foralumab, a Fully Human Anti-CD3 Antibody Being Developed as an Oral Therapy for NASH and Autoimmune Diseases
More volatile equity markets impact the buying and selling activity of our top managers.
Increased investor inflows and portfolio reshuffling (driven in part by a fairly valued market), has added breadth to the high-conviction and new-money purchases we've seen so far from our top managers.
Our top-rated stocks continue to do well, turning in very respectable performance in 2006. I'm happy that our patient strategy of recommending only stocks trading at a price that includes a reasonable margin of safety is paying off nicely for consumers of our research. As we have for the past few ...